← Back to Search

Cancer Vaccine

GRT-C903 for Solid Tumors

Phase 1 & 2
Waitlist Available
Research Sponsored by Gritstone Oncology, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

This trial tests two special vaccines combined with a treatment that helps the body fight hard-to-treat cancers. The vaccines help the body recognize and attack cancer cells. The goal is to see if this combination is safe and effective in fighting these cancers.

Eligible Conditions
  • Shared Neoantigen-Positive Solid Tumors
  • Colorectal Cancer
  • Non-Small Cell Lung Cancer
  • Pancreatic Cancer
  • Solid Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Phase 2Experimental Treatment4 Interventions
* GRT-C903 * GRT-R904 * nivolumab * ipilimumab Phase 2 for some patients includes a monthly or every two month treatment schedule
Group II: Phase 1Experimental Treatment4 Interventions
* GRT-C903 * GRT-R904 * nivolumab * ipilimumab
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GRT-C903
2019
Completed Phase 2
~40
Nivolumab
FDA approved
GRT-R904
2019
Completed Phase 2
~40
Ipilimumab
FDA approved

Find a Location

Who is running the clinical trial?

Gritstone Oncology, Inc.Lead Sponsor
5 Previous Clinical Trials
884 Total Patients Enrolled
Gritstone bio, Inc.Lead Sponsor
8 Previous Clinical Trials
1,308 Total Patients Enrolled
Bristol-Myers SquibbIndustry Sponsor
2,682 Previous Clinical Trials
4,129,530 Total Patients Enrolled

Media Library

GRT-C903 (Cancer Vaccine) Clinical Trial Eligibility Overview. Trial Name: NCT03953235 — Phase 1 & 2
Solid Tumors Research Study Groups: Phase 2, Phase 1
Solid Tumors Clinical Trial 2023: GRT-C903 Highlights & Side Effects. Trial Name: NCT03953235 — Phase 1 & 2
GRT-C903 (Cancer Vaccine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03953235 — Phase 1 & 2
~6 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top